The cholinergic system in subtypes of Alzheimer's disease: an in vivo longitudinal MRI study.
Alzheimer’s disease
Basal forebrain
Clinical trial
Heterogeneity
Nerve growth factor
Structural MRI
Subtypes
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
06 05 2020
06 05 2020
Historique:
received:
12
09
2019
accepted:
22
04
2020
entrez:
8
5
2020
pubmed:
8
5
2020
medline:
25
6
2021
Statut:
epublish
Résumé
The heterogeneity within Alzheimer's disease (AD) seriously challenges the development of disease-modifying treatments. We investigated volume of the basal forebrain, hippocampus, and precuneus in atrophy subtypes of AD and explored the relevance of subtype stratification in a small clinical trial on encapsulated cell biodelivery (ECB) of nerve growth factor (NGF) to the basal forebrain. Structural MRI data was collected for 90 amyloid-positive patients and 69 amyloid-negative healthy controls at baseline, 6-, 12-, and 24-month follow-up. The effect of the NGF treatment was investigated in 10 biopsy-verified AD patients with structural MRI data at baseline and at 6- or 12-month follow-up. Patients were classified as typical, limbic-predominant, hippocampal-sparing, or minimal atrophy AD, using a validated visual assessment method. Volumetric analyses were performed using a region-of-interest approach. All AD subtypes showed reduced basal forebrain volume as compared with the healthy controls. The limbic-predominant subtype showed the fastest basal forebrain atrophy rate, whereas the minimal atrophy subtype did not show any significant volume decline over time. Atrophy rates of the hippocampus and precuneus also differed across subtypes. Our preliminary data from the small NGF cohort suggest that the NGF treatment seemed to slow the rate of atrophy in the precuneus and hippocampus in some hippocampal-sparing AD patients and in one typical AD patient. The cholinergic system is differentially affected in distinct atrophy subtypes of AD. Larger studies in the future should confirm that this differential involvement of the cholinergic system may contribute to subtype-specific response to cholinergic treatment. Our preliminary findings suggest that future clinical trials should target specific subtypes of AD, or at least report treatment effects stratified by subtype. ClinicalTrials.gov identifier: NCT01163825. Registered 14 July 2010.
Sections du résumé
BACKGROUND
The heterogeneity within Alzheimer's disease (AD) seriously challenges the development of disease-modifying treatments. We investigated volume of the basal forebrain, hippocampus, and precuneus in atrophy subtypes of AD and explored the relevance of subtype stratification in a small clinical trial on encapsulated cell biodelivery (ECB) of nerve growth factor (NGF) to the basal forebrain.
METHODS
Structural MRI data was collected for 90 amyloid-positive patients and 69 amyloid-negative healthy controls at baseline, 6-, 12-, and 24-month follow-up. The effect of the NGF treatment was investigated in 10 biopsy-verified AD patients with structural MRI data at baseline and at 6- or 12-month follow-up. Patients were classified as typical, limbic-predominant, hippocampal-sparing, or minimal atrophy AD, using a validated visual assessment method. Volumetric analyses were performed using a region-of-interest approach.
RESULTS
All AD subtypes showed reduced basal forebrain volume as compared with the healthy controls. The limbic-predominant subtype showed the fastest basal forebrain atrophy rate, whereas the minimal atrophy subtype did not show any significant volume decline over time. Atrophy rates of the hippocampus and precuneus also differed across subtypes. Our preliminary data from the small NGF cohort suggest that the NGF treatment seemed to slow the rate of atrophy in the precuneus and hippocampus in some hippocampal-sparing AD patients and in one typical AD patient.
CONCLUSIONS
The cholinergic system is differentially affected in distinct atrophy subtypes of AD. Larger studies in the future should confirm that this differential involvement of the cholinergic system may contribute to subtype-specific response to cholinergic treatment. Our preliminary findings suggest that future clinical trials should target specific subtypes of AD, or at least report treatment effects stratified by subtype.
TRIAL REGISTRATION
ClinicalTrials.gov identifier: NCT01163825. Registered 14 July 2010.
Identifiants
pubmed: 32375872
doi: 10.1186/s13195-020-00620-7
pii: 10.1186/s13195-020-00620-7
pmc: PMC7203806
doi:
Substances chimiques
Cholinergic Agents
0
Banques de données
ClinicalTrials.gov
['NCT01163825']
Types de publication
Clinical Trial
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
51Références
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Alzheimers Dement. 2014 Oct;10(5 Suppl):S344-53
pubmed: 24418052
Alzheimers Dement. 2005 Jul;1(1):55-66
pubmed: 17476317
J Comp Neurol. 2013 Dec 15;521(18):4124-44
pubmed: 23852922
Eur Radiol. 2016 Aug;26(8):2597-610
pubmed: 26560730
Front Aging Neurosci. 2014 Oct 07;6:264
pubmed: 25339897
Prog Brain Res. 2004;145:67-78
pubmed: 14650907
IEEE Trans Med Imaging. 2016 Feb;35(2):612-21
pubmed: 26452275
Brain. 2017 Mar 1;140(3):735-747
pubmed: 28003242
Alzheimers Dement. 2015 Nov;11(11):1316-28
pubmed: 25676388
J Neurol Neurosurg Psychiatry. 1992 Oct;55(10):967-72
pubmed: 1431963
Alzheimers Dement. 2019 Mar;15(3):400-409
pubmed: 30439333
J Comp Neurol. 1983 Feb 20;214(2):170-97
pubmed: 6841683
Nat Med. 2005 May;11(5):551-5
pubmed: 15852017
Mol Cell Neurosci. 2002 Jan;19(1):88-96
pubmed: 11817900
Lancet Neurol. 2011 Sep;10(9):785-96
pubmed: 21802369
Alzheimers Dement (N Y). 2018 May 03;4:195-214
pubmed: 29955663
Sci Rep. 2017 Apr 18;7:46263
pubmed: 28417965
Hum Brain Mapp. 2019 Feb 15;40(3):868-878
pubmed: 30311315
Lancet. 2000 Dec 16;356(9247):2031-6
pubmed: 11145488
Alzheimers Res Ther. 2016 Jul 07;8(1):30
pubmed: 27389402
Cereb Cortex. 2010 Jul;20(7):1685-95
pubmed: 19889714
Neurobiol Dis. 2007 Apr;26(1):47-55
pubmed: 17270453
J Intern Med. 2015 Sep;278(3):277-90
pubmed: 25752192
Ann Neurol. 2009 Apr;65(4):403-13
pubmed: 19296504
Neurobiol Aging. 2018 May;65:98-108
pubmed: 29455029
Eur Radiol. 2011 Dec;21(12):2618-25
pubmed: 21805370
Brain. 2018 Mar 1;141(3):903-915
pubmed: 29309600
J Magn Reson Imaging. 2008 Apr;27(4):685-91
pubmed: 18302232
Neurology. 2020 Mar 10;94(10):436-448
pubmed: 32047067
Dement Geriatr Cogn Disord. 2012;33(1):18-28
pubmed: 22377499
Neurobiol Aging. 2018 Oct;70:18-29
pubmed: 29935417
Acta Neuropathol Commun. 2015 Feb 10;3:10
pubmed: 25853173
Nat Commun. 2016 Nov 04;7:13249
pubmed: 27811848
PLoS One. 2015 Nov 30;10(11):e0142756
pubmed: 26618360
J Alzheimers Dis. 2015;43(3):1059-72
pubmed: 25147108
Neurology. 1984 Jul;34(7):939-44
pubmed: 6610841
Front Neurosci. 2019 Feb 05;13:38
pubmed: 30804738
Brain Stimul. 2015 Jul-Aug;8(4):838-9
pubmed: 25991080
Neuroimage. 2020 May 1;211:116607
pubmed: 32035186
Neuroimage. 2007 Oct 15;38(1):95-113
pubmed: 17761438
Expert Rev Neurother. 2008 Nov;8(11):1703-18
pubmed: 18986241
Brain. 2015 Oct;138(Pt 10):2814-33
pubmed: 26283673
Cereb Cortex. 2016 Jun;26(6):2411-2426
pubmed: 25840425
Front Neurol. 2019 May 28;10:524
pubmed: 31191430
Trends Ecol Evol. 2009 Mar;24(3):127-35
pubmed: 19185386
Alzheimers Dement. 2017 Mar;13(3):205-216
pubmed: 27697430
J Neurol Neurosurg Psychiatry. 2005 Mar;76(3):320-4
pubmed: 15716519
J Mol Cell Biol. 2014 Feb;6(1):13-26
pubmed: 24431301
Neurology. 1993 Nov;43(11):2412-4
pubmed: 8232972
J Neurosurg. 2012 Aug;117(2):340-7
pubmed: 22655593
Lancet Neurol. 2012 Oct;11(10):868-77
pubmed: 22951070
J Alzheimers Dis. 2014;40(3):687-700
pubmed: 24503619